Apixaban for Deep Vein Thrombosis Treatment

Introduction to Apixaban

• The American College of Chest Physicians and American Society of Hematology suggest using apixaban over warfarin for DVT treatment in patients without cancer, with a Grade 2B recommendation 2, 1

Clinical Efficacy

• Apixaban reduces major bleeding risk by 37% compared to warfarin/LMWH, representing 6 fewer major bleeding events per 1,000 patients treated 1
• Apixaban has equivalent efficacy for preventing recurrent VTE and mortality compared to conventional enoxaparin/warfarin therapy 2, 1

Treatment Guidelines

• The standard treatment regimen is 10 mg orally twice daily for the first 7 days, then 5 mg twice daily for the remainder of therapy, according to the American College of Cardiology 1
• For extended prevention after completing initial treatment, the dose is reduced to 2.5 mg twice daily 1

Special Populations

• For cancer-associated DVT, LMWH remains first-line therapy, though apixaban is an acceptable alternative, as recommended by the American Society of Clinical Oncology 5, 1
• Apixaban has shown lower or similar rates of recurrent VTE compared to dalteparin in cancer patients 4

Contraindications and Cautions

• Avoid apixaban in patients with severe renal impairment (CrCl <15 mL/min) or severe hepatic impairment 1, 4
• Use apixaban with caution in patients with moderate renal dysfunction, as 27% of the drug undergoes renal elimination 1, 4

Monitoring and Follow-Up

• No routine laboratory monitoring is required, but assess renal function before initiating therapy and periodically thereafter, especially in patients with moderate renal impairment 1, 4